tislelizumab
novartis,beigene
['truce-02', 'bladder', 'tislelizumab', 'urothelial', 'biomarker']
#asco22 truce-02: promising response for tislelizumab + nab-paclitaxel for high-risk non-muscle-invasive urothelial #bladder carcinoma! interesting biomarker analysis too. 
Director, @danaFarber_GU & International Strategic Initiatives @DanaFarber. Kohlberg Prof. of Medicine @Harvardmed. @PanMass rider. #SoccerIsLife. Views Mine.